top of page
LogoWix.jpg
Search

Regenerative Research Roundup – May 2026

Welcome to the Regenerative Research Roundup, where we look through recently published research and bring you the best of the best in a quick-to-read digest.


This month, we explore:

  • Recommendations and best practices for intra‑articular PRP by the American Academy of Physical Medicine and Rehabilitation (AAPM&R), including dosing thresholds, leukocyte profiles, and administration considerations

  • Expert consensus on viscosupplementation formulations and properties, including molecular weight, additives, and rheological characteristics

  • Evidence‑based recommendations and best practices for hyaluronic acid use in knee OA from the LATINVISCO group

  • An umbrella meta‑analysis evaluating intra‑articular PRP for knee OA with comparison to HA, corticosteroids, and combination therapy

   

Let's dive in!



AAPM&R guidance statement on platelet rich plasma for knee osteoarthritis


PM&R // LOE: I


Consensus statement by the American Academy of Physical Medicine and Rehabilitation (AAPM&R) addressing the use of intra-articular PRP for knee osteoarthritis. The technical expert panel (TEP) compared clinical indications, PRP preparation variables, and best-practice administration principles – deriving 5 evidence-based clinical recommendations and 11 consensus-based best practices.


Key Findings:

  • TEP recommended ≥10 billion platelet dosage to improve long-term clinical outcomes for knee OA

  • TEP recommended considering PRP for patients with mild-to-moderate knee OA with persistent symptoms despite conservative care.

  • For patients with severe knee OA involving subchondral bone, TEP recommended the use of intraosseous injection of PRP to be considered in addition to intra-articular PRP

  • Both LR and LP PRP can be considered and have demonstrated long-term clinical benefit for treatment of knee OA


Clinical Perspective:


This massive AAPM&R guidance statement provides credible mode of assessing current PRP best practices alongside expert driven recommendations. To no surprise, consensus has recognized the dosage threshold (≥10 billion platelets) for sustained outcomes in knee OA – which has been well documented throughout the literature (Bansal et al., 2021).


This is further emphasized with the lack of superiority of LP-PRP for knee OA, as although leukocyte content is important for biological activity and signal amplification within the chondrocyte matrix – in terms of patient discomfort – ultimately the determining factor for tissue repairs is dose.



Expert consensus on hyaluronic acid injections for knee osteoarthritis: a patient-centered approach


Aging Clinical and Experimental Research // LOE: V

 

This international expert consensus review evaluates contemporary intra‑articular hyaluronic acid formulations for knee OA, placing emphasis on formulation characteristics; including molecular weight, cross‑linking, and polyols such as sorbitol – and how these characteristics influence clinical performance, tolerability, and patient preference.


Key Findings:

  • HA formulations containing sorbitol (Synolis VA) have been shown in vitro, to reduce IL‑1β–induced nitric oxide production, iNOS expression, PGEâ‚‚ levels, and MMP‑13 activity, alongside partial restoration of redox balance

  • Hybrid molecular weight HA formulations have shown superior efficacy and pain reduction from a single injection over 24 weeks compared to PRP, in a cohort of professional football players with degenerative cartilage lesions

  • Patients should be educated on the risks and benefits of diverse formulations available; including molecular weight and cross-linking density which may influence efficacy and tolerability

  • Evaluated rheological properties across formulations, additives, molecular weights etc…

 

Clinical Perspective:


This consensus reinforces that intra-articular HA is not a uniform treatment and that formulation variables (polyols, molecular weight, and cross-linking density) can meaningfully influence both biological behaviour and patient sensitivity. In the ideal case, the responsible clinician should match formulation towards their patient needs, risk, tolerance and treatment goals, with patient education being central to decision-making.

 


LatinVisco: A Latin American Expert Consensus on Viscosupplementation for Knee Osteoarthritis


Complementary Therapies in Medicine // LOE: I


LATINVISCO group consistent of multidisciplinary specialists from various Latin American countries with the goal of developing evidence-based recommendations on viscosupplementation (VS) and other intra-articular therapies (IA). Recommendations were evaluated based off consensus and quality of evidence.


Key Findings:

  • VS is recommended as an analgesic treatment providing pain relief throughout all stages of knee OA – strongly recommended + quality evidence

  • Compared to corticosteroids, VS provides more durable outcomes with greater safety profile – strongly recommended + quality evidence

  • PRP shows superior long-term pain reduction compared to VS, but recommended combination of PRP + VS for knee OA – strongly recommended + quality evidence

  • VS can be used on a prolonged basis, in single or multiple doses as they are effective and safe – strongly recommended + quality evidence


Clinical Perspective:


This consensus extends beyond symptom relief, considering HA behavior within the osteoarthritic joint, including chondrocyte interactions, peri‑operative use, and formulation strategies aimed at preserving intra‑articular HA activity. The emphasis on viscoinduction and protective adjuncts like mannitol reflects a growing focus on HA therapies that are designed not just to lubricate the joint, but to help HA function more effectively within the inflammatory environment of OA.


 

Efficacy and Safety of Platelet-Rich Plasma in Knee Osteoarthritis: Umbrella Meta-Analysis Based on Clinical Evidence, Methodological Quality and Therapeutic Positioning


MDPI // LOE: I


Umbrella review comprised of 7 meta-analyses consisting of RCTs evaluating intra-articular PRP against hyaluronic acid (HA), corticosteroids, placebo, or combination therapy for knee OA.


Key Findings:

  • Across pooled analyses, PRP consistently outperformed HA and placebo for pain and functional outcomes at 3–12 months.

  • Combination therapy of PRP + HA showed improved WOMAC and VAS scores compared to PRP alone, while also showing increased durability and improved safety profile: by inhibiting synovial inflammation and modulating cytokine profiles


Clinical Perspective:


This study largely reinforces what been reported throughout MSK literature being that intra-articular PRP provides more durable improvements in pain and function compared to HA in knee OA. However, the synergistic effect that PRP and HA have within the chondrocyte matrix, with their overlapping immune modulation seems to be the driving force for improving OA function in the early stage – in cases where monotherapy may be insufficient.



 
 
 
bottom of page